Jade Biosciences, Inc.
NCM: JBIOLive Quote
📈 ZcoreAI Score
Our AI model analyzes Jade Biosciences, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get JBIO Z-Score →About Jade Biosciences, Inc.
Healthcare
Biotechnology
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The compnay also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
📊 Fundamental Analysis
Jade Biosciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -89.2%, which indicates that capital utilization is currently under pressure.
At a current price of $17.89, JBIO currently trades near the bottom of its 52-week range (12%), indicating potential value or weakness (Range: $6.57 - $100.10).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
Key Financials
Market Cap
$882.27M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
--
52W High
$100.10
52W Low
$6.57
Avg Volume
400K
Day High
Day Low